Ronald R Tuttle

US Patent:

56439679, Jul 1, 1997

Filed:

Mar 18, 1993

Appl. No.:

8/037789

Inventors:

David B. Anderson - Greenfield IN
Klaus K. Schmiegel - Indianapolis IN
Edward L. Veenhuizen - Greenfield IN
Ronald R. Tuttle - Escondido CA

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31135

US Classification:

514653

Abstract:

beta. -Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.

US Patent:

52862526, Feb 15, 1994

Filed:

Dec 11, 1990

Appl. No.:

7/625362

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

57600015, Jun 2, 1998

Filed:

May 22, 1995

Appl. No.:

8/447143

Inventors:

Beverly E. Girten - San Diego CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Mark J. Suto - San Deigo CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

US Patent:

59655364, Oct 12, 1999

Filed:

Jun 14, 1996

Appl. No.:

8/666564

Inventors:

Allen Barry Cohen - late of Tyler TX
Edmund J. Miller - Flint TX
Shinichiro Hayashi - Tyler TX
Anna K. Kurdowska - Tyler TX
Ronald R. Tuttle - Escondido CA

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3800
A61K 3802
C07K 500
C07K 700

US Classification:

514 17

Abstract:

Disclosed are methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2. beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis.

US Patent:

51083639, Apr 28, 1992

Filed:

Feb 9, 1989

Appl. No.:

7/308683

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

52344045, Aug 10, 1993

Filed:

Oct 11, 1991

Appl. No.:

7/775735

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

57417741, Apr 21, 1998

Filed:

Sep 27, 1996

Appl. No.:

8/722279

Inventors:

Beverly E. Girten - San Diego CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

514 8

Abstract:

The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.

US Patent:

57261563, Mar 10, 1998

Filed:

Sep 12, 1995

Appl. No.:

8/527056

Inventors:

Beverly E. Girten - San Diego CA
Ali Andalibi - San Diego CA
Amaresh Basu - San Diego CA
Patrick Fagan - Escondido CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Paul Omholt - San Diego CA
Ronald R. Tuttle - Escondido CA
Mark J. Suto - San Diego CA
Patricia A. Weber - Stevensville MT

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.